
1. kvartal 2023: Jobindex følger budgettet og fastholder forventningerne
- Jobindex' omsætning og resultat i årets første kvartal var i tråd med forventningerne: Nettoomsætningen var 106 mio. kr., og resultatet før renter og skat endte på 36 mio. kr. Det er henholdsvis 13% og 34% lavere end første kvartal 2022.
- Jobmarkedet er fortsat stærkt på uændret niveau: De seneste otte måneder har antallet af jobannoncer på internettet ligget på ca. 10% over niveauet før corona.
- Jobindex forventer fortsat en omsætning i niveauet 440 mio. kr. og et overskud før renter og skat i niveauet 150 mio. kr. for hele 2023.
Stærkt dansk jobmarked
"Siden efteråret sidste år har jobmarkedet ligget forholdsvis stabilt," fortæller direktør Kaare Danielsen i forbindelse med Jobindex-koncernens seneste kvartalsmeddelelse og fortsætter: "Det understøtter vores forventninger om, at der ikke er store udfordringer lige om hjørnet: Det danske jobmarked er stærkt og aktivt. Beskæftigelsen sætter nye rekorder og steg med knap 5000 personer i marts 2023, og de fleste økonomer har opjusteret deres forventninger og forventer en behersket med positiv vækst i BNP i 2023."
Uændrede forventninger
Jobindex-koncernens omsætning og resultat i første kvartal når de mål, der er forudsat i forventninger og budgetter, og Jobindex fastholder sine forventninger til hele året om en omsætning i niveauet 440 mio. kr. og et resultat før renter og skat i niveauet 150 mio. kr. Forventningerne er baseret på en forudsætning om, at det høje niveau i antallet af jobannoncer fortsætter.
"Selv om vi, som mange andre virksomheder, udfordres både på omsætning og på omkostningssiden, har vi startet med flotte resultater. Vi er især glade for at konstatere, at såvel vores rekrutteringsydelser som de aktiviteter, der udføres i Computerworld, oplever en absolut beskeden, men fortsat positiv vækst i omsætningen," slutter Kaare Danielsen.
Yderligere oplysninger
Direktør Kaare Danielsen, telefon 20735010, email kd@jobindex.dk
Certified Adviser Jakob Tolstrup Kristensen, email jakob.tolstrup@cwicf.com
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Mowi ASA (OSE: MOWI): 2023 Salmon Farming Industry Handbook9.6.2023 06:30:00 CEST | Press release
Please find attached the 2023 version of the Salmon Farming Industry Handbook. The handbook is also available on our website www.mowi.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2023 Salmon Farming Industry Handbook
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor